Intangible Assets, net (Narrative) (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended		6 Months Ended						6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014 product	Jun. 30, 2013	Jun. 30, 2014 Sky Growth Merger [Member] Developed products [Member]	Jun. 30, 2014 Sky Growth Merger [Member] Subsequently Developed In Process Research and Development [Member]	Jun. 30, 2013 Watson/Actavis Divestiture Products [Member]	Nov. 06, 2012 Watson/Actavis Divestiture Products [Member] drug_application product	Jun. 30, 2014 Watson/Actavis Divestiture Products [Member]	Jun. 30, 2014 JHP Group Holdings [Member] product annual_IPRD_group	Jun. 30, 2014 JHP Group Holdings [Member] Developed products [Member]	Jun. 30, 2014 JHP Group Holdings [Member] Trade Names [Member]
Intangible Assets, Net (Excluding Goodwill) [Line Items]
Amortization expense related to intangible assets			$ 83,162	$ 81,536
Weighted average amortization period					6 years	7 years			6 years		10 years	5 years
Number of generic products with marketing rights acquired through merger (products)								5
Number of abbreviated new drug applications awaiting regulatory approval (drug applications)								8
Number of IPR&D groups created										6
Intangible asset impairment	$ 35,863	$ 466	$ 77,621	$ 466			$ 466
Number of products impaired not expected to achieve forecasted operating results			6
Number of discontinued products			1							1